Cargando…
Recent Progress in Mass Spectrometry-Based Metabolomics in Major Depressive Disorder Research
Major depressive disorder (MDD) is a serious mental illness with a heavy social burden, but its underlying molecular mechanisms remain unclear. Mass spectrometry (MS)-based metabolomics is providing new insights into the heterogeneous pathophysiology, diagnosis, treatment, and prognosis of MDD by re...
Autores principales: | Liu, Mingxia, Ma, Wen, He, Yi, Sun, Zuoli, Yang, Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647556/ https://www.ncbi.nlm.nih.gov/pubmed/37959849 http://dx.doi.org/10.3390/molecules28217430 |
Ejemplares similares
-
Microglia in depression: an overview of microglia in the pathogenesis and treatment of depression
por: Wang, Haixia, et al.
Publicado: (2022) -
Cerebrospinal fluid proteome evaluation in major depressive disorder by mass spectrometry
por: Franzen, Avery D., et al.
Publicado: (2020) -
Metabolomics Research in Periodontal Disease by Mass Spectrometry
por: Tsuchida, Sachio, et al.
Publicado: (2022) -
Untargeted Plasma Metabolomic Profiling in Patients with Major Depressive Disorder Using Ultra-High Performance Liquid Chromatography Coupled with Mass Spectrometry
por: Homorogan, Claudia, et al.
Publicado: (2021) -
Tissue-Specific Oxysterols as Predictors of Antidepressant (Escitalopram) Treatment Response in Patients With Major Depressive Disorder
por: Sun, Zuoli, et al.
Publicado: (2023)